Journal
LUPUS
Volume 22, Issue 4, Pages 350-360Publisher
SAGE PUBLICATIONS LTD
DOI: 10.1177/0961203312469453
Keywords
B lymphocyte stimulator; B cell-activating factor; peripheral tolerance; belimumab; toll-like receptor
Categories
Funding
- NIAID NIH HHS [R01 AI054488, T32 AI055428] Funding Source: Medline
Ask authors/readers for more resources
B lymphocyte stimulator (BLyS; also known as B cell activating factor (BAFF)) plays a key role in peripheral B cell tolerance. Mounting evidence indicates that B cell tolerance can be either broken or modulated by deliberately manipulating BLyS levels, and belimumab, a BLyS-neutralizing antibody, was recently approved for the treatment of systemic lupus erythematosus (SLE). Thus, intense investigation has focused on understanding how therapeutics targeting BLyS may work, and accumulating evidence suggests multiple points of action. BLyS signaling, in conjunction with B cell receptor (BCR) signaling, determines the size and quality of the mature primary B cell compartment. Moreover, BLyS family members play roles in antigen-experienced B cell selection and differentiation. Together, these findings have implications for the continued development of novel therapeutics that target BLyS. Lupus (2013) 22, 350-360.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available